NCT06481709View on ClinicalTrials.gov

Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Bioavailability
Interventions
DRUG

RLF-OD032

100 mg/mL oral suspension

DRUG

Kuvan

100 mg powder for oral solution

Trial Locations (1)

M1S3V6

Pharma Medica Research Inc. 4770 Sheppard Ave E,, Toronto

Sponsors
All Listed Sponsors
lead

APR Applied Pharma Research s.a.

OTHER